Market Fallers: GlaxoSmithKline plc & Centrica PLC

GlaxoSmithKline plc
[shareaholic app="share_buttons" id_name="post_below_content"]

The stock price for GlaxoSmithKline plc ticker lookup code: LON:GSK has moved down -2.47% or -37.6 points during today’s session so far. Investors did not seem confident while the stock has been in play. Range high for the period so far is 1512.58 and a low of 1480. The total volume of shares traded by this point was 1,468,466 whilst the daily average number of shares exchanged is just 8,085,541. The 52 week high for the shares is 1648.8 which is 126.2 points in difference on the previous days close and a 52 week low being 1179.39 is a variance of 343.21 points. GlaxoSmithKline plc now has a 20 simple moving average of 1500.97 and now the 50 day SMA of 1512.65. Market capitalisation for the company is £73,729.10m at the time of this report. The share price is in Great British pence. Mcap is measured in GBP. This article was written with the last trade for GlaxoSmithKline plc being recorded at Wednesday, February 6, 2019 at 12:02:41 PM GMT with the stock price trading at 1485 GBX.

 

Shares in Centrica PLC ticker code: LON:CNA has slid -2.24% or -3.15 points throughout today’s trading session so far. Traders aired on the negative side during the trading session. The period high has peaked at 139.4 dropping as low as 135.5. The total volume traded so far comes to 9,456,763 with the daily average at 20,742,333. A 52 week high for the stock is 164.5 equating to 23.95 points difference from the previous close and the 52 week low at 123.1 which is a difference of 17.45 points. Centrica PLC now has a 20 SMA at 136.65 and the 50 day MA at 137.1. The current market cap is £7,821.82m at the time of this report. The share price is in Great British pence. Mcap is measured in GBP. This article was written with the last trade for Centrica PLC being recorded at Wednesday, February 6, 2019 at 12:02:38 PM GMT with the stock price trading at 137.4 GBX.

Twitter
LinkedIn
Facebook
Email
Reddit
Telegram
WhatsApp
Pocket
Find more news, interviews, share price & company profile here for:
    GSK's Arexvy vaccine receives approval in Japan to protect adults aged 50-59 at increased risk from severe RSV infection, expanding its coverage.
    GSK Plc reports Q3 2024 results with strong growth in Specialty Medicines offsetting lower Vaccine sales. Core earnings rose by 5%, despite Zantac charges.
    GSK's new antibiotic gepotidacin earns FDA's Priority Review, marking potential first new uUTI oral treatment in 20 years, with decision due March 2025.

      Search

      Search